Literature DB >> 26650885

Biomarkers of Cervical Inflammation and Immunity Associated with Cervical Shedding of HIV-1.

Christine Mauck1, Pai-Lien Chen2, Charles S Morrison3, Raina N Fichorova4, Cynthia Kwok2, Tsungai Chipato5, Robert A Salata6, Gustavo F Doncel1.   

Abstract

BACKGROUND: Cervicovaginal HIV shedding is associated with increased female-to-male and mother-to-child transmission. Genital inflammation may increase shedding through cytokines/chemokines which recruit and activate HIV target cells. We evaluated whether cervical immune mediators present before seroconversion affected HIV shedding and whether mediators differed between shedders and nonshedders.
METHODS: We used cervical samples from 187 African women with documented HIV seroconversion in the Hormonal Contraception and HIV study. Samples were from the two visits before seroconversion (T-2 and/or T-1), and/or at seroconversion (T0), and/or the two visits (T + 1 and/or T + 2) after seroconversion. We measured interleukin (IL)-1β, IL-1 Receptor Antagonist (IL-1RA), IL-6, IL-8, RANTES (Regulated on Activation, Normal T-Cell Expressed and Secreted), MIP-3α, vascular endothelial growth factor (VEGF), Intercellular Adhesion Molecule-1 (ICAM-1), secretory leukocyte protease inhibitor (SLPI), and BD-2 and used the Wilcoxon test and generalized linear models to evaluate the association between mediators and shedding.
RESULTS: The only immune mediator that differed at T-1 was RANTES, which was higher among shedders (p ≤ .05). HIV seroconversion was followed by significant decreases in many mediators, but a significant increase in RANTES. The magnitude of the change was significantly different for shedders versus nonshedders with regard to RANTES (increased in both groups, significantly more so in shedders), SLPI (decreased in both groups, significantly more so in shedders), and MIP-3α (decreased in shedders and increased in nonshedders). At T0, shedders had lower levels of SLPI and MIP-3α than nonshedders.
CONCLUSIONS: In this study, a specific immune mediator profile was associated with risk of cervical HIV shedding. Higher and increasing levels of RANTES and lower and decreasing levels of SLPI and MIP-3α were associated with increased risk of HIV shedding.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26650885      PMCID: PMC4845652          DOI: 10.1089/AID.2015.0088

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  29 in total

1.  Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team.

Authors:  P S Reichelderfer; R W Coombs; D J Wright; J Cohn; D N Burns; S Cu-Uvin; P A Baron; M H Coheng; A L Landay; S K Beckner; S R Lewis; A A Kovacs
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

Review 2.  Guiding the vaginal microbicide trials with biomarkers of inflammation.

Authors:  Raina N Fichorova
Journal:  J Acquir Immune Defic Syndr       Date:  2004-10       Impact factor: 3.731

3.  The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission.

Authors:  R N Fichorova; L D Tucker; D J Anderson
Journal:  J Infect Dis       Date:  2001-07-16       Impact factor: 5.226

4.  Hormonal contraception and the risk of HIV acquisition.

Authors:  Charles S Morrison; Barbra A Richardson; Francis Mmiro; Tsungai Chipato; David D Celentano; Joanne Luoto; Roy Mugerwa; Nancy Padian; Sungwal Rugpao; Joelle M Brown; Peter Cornelisse; Robert A Salata
Journal:  AIDS       Date:  2007-01-02       Impact factor: 4.177

5.  Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Authors:  L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

6.  Early HIV-1 infection is associated with reduced frequencies of cervical Th17 cells.

Authors:  Lyle R McKinnon; Billy Nyanga; Connie J Kim; Preston Izulla; Jessie Kwatampora; Makobu Kimani; Kamnoosh Shahabi; Nelly Mugo; Jennifer S Smith; A Omu Anzala; Joshua Kimani; Rupert Kaul
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

7.  Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

Authors:  Michael M Lederman; Ronald S Veazey; Robin Offord; Donald E Mosier; Jason Dufour; Megan Mefford; Michael Piatak; Jeffrey D Lifson; Janelle R Salkowitz; Benigno Rodriguez; Andrew Blauvelt; Oliver Hartley
Journal:  Science       Date:  2004-10-15       Impact factor: 47.728

8.  Short communication: genital tumor growth factor-β1 levels in HIV-infected Indian women are associated with reduced levels of innate antimicrobial products and increased HIV shedding.

Authors:  Madhuri Thakar; Rahul Patil; Subodh Shukre; Shubhangi Bichare; Poonam Kadam; Priyanka Khopkar; Manisha Ghate; Ramesh Paranjape
Journal:  AIDS Res Hum Retroviruses       Date:  2014-03-13       Impact factor: 2.205

9.  Cervical human immunodeficiency virus type 1 shedding is associated with genital beta-chemokine secretion.

Authors:  A K Iversen; L Fugger; J Eugen-Olsen; U Balslev; T Jensen; S Wahl; J Gerstoft; J I Mullins; P Skinhoj
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

10.  The Contribution of Cervicovaginal Infections to the Immunomodulatory Effects of Hormonal Contraception.

Authors:  Raina N Fichorova; Pai-Lien Chen; Charles S Morrison; Gustavo F Doncel; Kevin Mendonca; Cynthia Kwok; Tsungai Chipato; Robert Salata; Christine Mauck
Journal:  MBio       Date:  2015-09-01       Impact factor: 7.867

View more
  10 in total

1.  High Levels of Inflammatory Cytokines in the Reproductive Tract of Women with BV and Engaging in Intravaginal Douching: A Cross-Sectional Study of Participants in the Women Interagency HIV Study.

Authors:  Maria L Alcaide; Violeta J Rodriguez; Megan R Brown; Suresh Pallikkuth; Kristopher Arheart; Octavio Martinez; Margaret Roach; Raina N Fichorova; Deborah L Jones; Savita Pahwa; Margaret A Fischl
Journal:  AIDS Res Hum Retroviruses       Date:  2017-01-03       Impact factor: 2.205

2.  A Longitudinal Assessment of Cervical Inflammation and Immunity Associated with HIV-1 Infection, Hormonal Contraception, and Pregnancy.

Authors:  Charles S Morrison; Raina Fichorova; Pai-Lien Chen; Cynthia Kwok; Jennifer Deese; Hidemi Yamamoto; Sharon Anderson; Tsungai Chipato; Robert Salata; Gustavo F Doncel
Journal:  AIDS Res Hum Retroviruses       Date:  2018-09-05       Impact factor: 2.205

3.  Female genital tract shedding of HIV-1 is rare in women with suppressed HIV-1 in plasma.

Authors:  Julie A E Nelson; Kristina De Paris; Catalina Ramirez; Andrew Edmonds; Katie R Mollan; Camden P Bay; Kara Compliment; Betsy C Herold; Kathryn Anastos; Howard Minkoff; Seble Kassaye; Dominika L Seidman; Audrey L French; Elizabeth T Golub; Anandi N Sheth; Christina Ochsenbauer; Ronald Swanstrom; Joseph J Eron; Adaora A Adimora
Journal:  AIDS       Date:  2020-01-01       Impact factor: 4.632

Review 4.  Barriers to HIV remission research in low- and middle-income countries.

Authors:  Theresa Rossouw; Joseph D Tucker; Gert U van Zyl; Kenly Sikwesi; Catherine Godfrey
Journal:  J Int AIDS Soc       Date:  2017-06-05       Impact factor: 5.396

5.  Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Authors:  Andrea Ries Thurman; Jill L Schwartz; Vivian Brache; Meredith R Clark; Timothy McCormick; Neelima Chandra; Mark A Marzinke; Frank Z Stanczyk; Charlene S Dezzutti; Sharon L Hillier; Betsy C Herold; Raina Fichorova; Susana N Asin; Christiane Rollenhagen; Debra Weiner; Patrick Kiser; Gustavo F Doncel
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

6.  Impact of reproductive aging on the vaginal microbiome and soluble immune mediators in women living with and at-risk for HIV infection.

Authors:  Kerry Murphy; Marla J Keller; Kathryn Anastos; Shada Sinclair; J Cooper Devlin; Qiuhu Shi; Donald R Hoover; Brian Starkman; Jamie McGillick; Caroline Mullis; Howard Minkoff; Maria Gloria Dominguez-Bello; Betsy C Herold
Journal:  PLoS One       Date:  2019-04-26       Impact factor: 3.752

7.  A pro-inflammatory CD8+ T-cell subset patrols the cervicovaginal tract.

Authors:  Laura Pattacini; Amanda Woodward Davis; Julie Czartoski; Florian Mair; Scott Presnell; Sean M Hughes; Ollivier Hyrien; Gretchen M Lentz; Anna C Kirby; Michael F Fialkow; Florian Hladik; Martin Prlic; Jennifer M Lund
Journal:  Mucosal Immunol       Date:  2019-07-16       Impact factor: 8.701

8.  Aberrant cervical innate immunity predicts onset of dysbiosis and sexually transmitted infections in women of reproductive age.

Authors:  Raina N Fichorova; Charles S Morrison; Pai-Lien Chen; Hidemi S Yamamoto; Yashini Govender; Damilola Junaid; Stanthia Ryan; Cynthia Kwok; Tsungai Chipato; Robert A Salata; Gustavo F Doncel
Journal:  PLoS One       Date:  2020-01-08       Impact factor: 3.240

Review 9.  Emergence of Nanotechnology to Fight HIV Sexual Transmission: The Trip of G2-S16 Polyanionic Carbosilane Dendrimer to Possible Pre-Clinical Trials.

Authors:  Ignacio Relaño-Rodríguez; Maria Ángeles Muñoz-Fernández
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

10.  Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel.

Authors:  Natalia Teleshova; Marla J Keller; José A Fernández Romero; Barbara A Friedland; George W Creasy; Marlena G Plagianos; Laurie Ray; Patrick Barnable; Larisa Kizima; Aixa Rodriguez; Nadjet Cornejal; Claudia Melo; Gearoff Cruz Rodriguez; Sampurna Mukhopadhyay; Giulia Calenda; Shweta U Sinkar; Thierry Bonnaire; Asa Wesenberg; Shimin Zhang; Kyle Kleinbeck; Kenneth Palmer; Mohcine Alami; Barry R O'Keefe; Patrick Gillevet; Hong Hur; Yupu Liang; Gabriela Santone; Raina N Fichorova; Tamara Kalir; Thomas M Zydowsky
Journal:  PLoS One       Date:  2022-01-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.